Jameson Legal

 

Resource

 

 

 

 

 

 

 

 

 

 

 

Freshfields advises Novartis on inter-conditional transaction

06 May 2014

Freshfields Bruckhaus Deringer is advising Novartis on the following inter-conditional transaction:

  * The acquisition of oncology products from GSK and the agreement to become GSK’s preferred commercialisation partner for its oncology pipeline for a US$14.5bn payment and up to US$1.5bn contingent on a development milestone
  * The formation of a world-leading consumer healthcare business in a joint venture with GSK, of which Novartis would own 36.5%
  * The sale to GSK of the Novartis Vaccines Division (excluding flu) for up to US$7.1bn plus royalties

Freshfields, alongside co-counsel Linklaters, is supporting the Novartis internal legal team which, in relation to this inter-conditional transaction, includes Felix R. Ehrat, Roy Papatheodorou, Jonathan Emery, Susan Jones, Frank Smith, Bill Miller, Nicola Smith, Kirsty Grant and David Emanuelson.

Separately, Freshfields is also advising Novartis on the sale of its Animal Health Division to Eli Lilly for US$5.4bn.

Freshfields is also supporting the Novartis internal legal team of Felix R. Ehrat, Roy Papatheodorou, Jonathan Emery, Susan Jones, Frank Smith, Andrew Webb and David Emanuelson on this transaction.

The Freshfields team is led by partners Jennifer Bethlehem (London, corporate), Julian Long (London, corporate), Andrew Craig (London, corporate), Doug Bacon (NYC, corporate), Julian Pritchard (NYC, corporate), Rod Carlton (London, antitrust), Paul Yde (Washington DC, antitrust), Alvaro Iza (Madrid, antitrust), Thomas Janssens (Brussels, antitrust), Colin Hargreaves (London, tax), Claude Stansbury (Washington DC, tax,) and Kathleen Healy (London, employment, pensions and benefits).

Other key members of the Freshfields team are, for London corporate: Richard Lister (partner), David Brooks (senior associate), Alison Smith (senior associate), Elizabeth Cameron (senior associate), Samira Afrasiabi (associate), Sayo Ogundele (associate), Stewart Walker (associate), Ryan Taylor (associate), Christina Flanagan (trainee), Leah Brown (trainee), Julia Chan (trainee), Bradley Hudson (trainee); for NYC corporate: Omar Pringle (associate), Paul Humphreys (associate), Erika Winkler (associate), Jennifer Ju (associate), Sarah Falder (trainee); for Hamburg corporate: Jochen Dieselhorst (partner), Börge Seeger (senior associate), Robert Auer (associate); for London antitrust: Colin Raftery (associate); for Washington DC, antitrust: Craig Minerva (associate), Justin Stewart-Teitelbaum (associate), Ilana Kattan (associate), Valeria Losco (associate), Harriet Dufn (trainee); for Brussels antitrust: Sara Bacchio (associate), Vera Coughlan (associate), Amaryllis Müller (associate), Deborah Faure (trainee); for Spain antitrust: Enrique Carrera (senior associate), Rafael Piqueras (associate), Ana Lapiedra Carmona (associate); for China anti-trust: Michael Han (partner), Ninette Dodoo (counsel); for London tax: Neel Acharya (associate); for Washington DC tax: Eschrat Rahimi-Laridjani (counsel); for London employment pensions and benefits: Harriet Gaillard (senior associate), Andrew Murphy (senior associate); for London real estate: Emma Kendall (partner), Tim Dodd (associate); and for NYC dispute resolution: Adam Siegel (partner), Michael Lacovara (partner).

Matter Type
M&A: Seller's Counsel
Industry
Healthcare, Life Sciences & Chemicals
News Category
M&A